Expanded access program of QINLOCK
Latest Information Update: 17 Nov 2020
At a glance
- Drugs Ripretinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 17 Nov 2020 New trial record
- 06 Nov 2020 According to a Medison Pharma media release, the compant Medison Israel is planning to submit QINLOCK for registration during Q1 2021 and commence an early access program (EAP) for Israeli patients immediately after.